PACB
Pacific Biosciences of Californ Healthcare Medical Devices
8/12
Innovation Score
Patent Activity
3/3
59 patents found
ALIAS_FUZZY
Cash Runway
2/3
30 months of cash remaining based on current burn rate.
Cash on hand: $276.0M
Cash on hand: $276.0M
Revenue Trajectory
1/3
Revenue: $160.0M
YoY Growth: +0.1%
YoY Growth: +0.1%
Management Quality
2/3
Insider ownership: 2.2%
SBC/Revenue: 10.5%
No reverse splits detected
SBC/Revenue: 10.5%
No reverse splits detected
Key Metrics
Market Cap
$484.5M
Revenue
$160.0M
Revenue Growth (YoY)
+0.1%
Cash on Hand
$276.0M
Cash Runway
30 months
Shares Outstanding
310.6M
Insider Ownership
2.2%
SBC / Revenue
10.5%
Sector / Industry
Healthcare / Medical Devices
Patents (59)
Match type: ALIAS_FUZZY
- Methods and compositions for sequencing double stranded nucleic acids
- Protected dye-labeled reagents
- High speed scanning system with acceleration tracking
- String graph assembly for polyploid genomes
- Calibrated focus sensing
7-Step Risk Assessment
How PACB maps to our micro cap methodology:
- Innovation Signal 59 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 30 months of runway. Comfortable buffer for execution.
- Revenue Trajectory +0.1% YoY growth on $160.0M revenue. Positive but moderate growth.
- Management Alignment Insiders hold 2.2% of shares. SBC is 10.5% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $484.5M company.
Financial Detail
Free Cash Flow
$-48.2M
FCF Yield
-10.0%
Return on Equity
-273.6%
Debt / Equity
29855.8%
Gross Margin
38.3%
Profit Margin
-80.3%
Operating Margin
-102.9%
Price / Book
195.00
Current Ratio
5.65
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-07-11